December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bioadaptives Inc (OP:BDPT)

0.0048 +0.0004 (+9.09%)
Streaming Delayed Price Updated: 3:54 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,115,757
Open 0.0046
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0044
Today's Range 0.0037 - 0.0053
52wk Range 0.0008 - 0.0700
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioAdaptives Highlights Michael Bisping's MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video
UFC Hall of Famer and MyndSystem ™ brand ambassador shares how the daytime formula fits into his preparation for live broadcasts, commentary, and podcasting. 
From BioAdaptives, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
Initial XcellaraHeart™ orders ship next week, marking the commercial launch of the Xcellara™ cellular wellness platform; Company prepares XcellaraResilience™ for October launch and highlights the... 
From BioAdaptives, Inc.
Via ACCESS Newswire

Performance

YTD
-78.2%
-78.2%
1 Month
+200.0%
+200.0%
3 Month
-15.8%
-15.8%
6 Month
-56.4%
-56.4%
1 Year
-84.0%
-84.0%

More News

Read More
News headline image
UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)
From BioAdaptives, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
From BioAdaptives, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
From BioAdaptives, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara(TM) "Supply and Direction" Platform
From BioAdaptiveas, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
From BioAdaptives, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor
From BioAdaptives, Inc.
Via ACCESS Newswire
News headline image
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform
From BioAdaptives, Inc.
Via ACCESS Newswire
InvestorNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Completes Manufacturing Readiness for Wellness Product Launch
Via Investor Brand Network
Topics Economy
BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) Details Xcellara(TM) Platform Strategy Ahead of XcellaraHeart(TM) Launch
Via Investor Brand Network
NetworkNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Announces Aug. 1 Launch of XcellaraHeart Cardiovascular Wellness Supplement
Via Investor Brand Network
BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification
Via Investor Brand Network
BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) Launches MyndSystem Cognitive Support Platform
Via Investor Brand Network
InvestorNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Launches MyndRenew Nighttime Supplement for Cognitive Recovery
Via Investor Brand Network
InvestorNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndSystem Platform and Website for Cognitive Performance and Recovery
Via Investor Brand Network
NetworkNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndMed Cognitive-Support Supplement Following Successful Testing and Strong Early Demand
Via Investor Brand Network
InvestorNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndMed Cognitive-Support Supplement Following Successful Testing and Strong Early Demand
Via Investor Brand Network
BioMedNewsBreaks — BioAdaptives, Inc. (OTCMKTS: BDPT) Receives WADA-Compliant Certification for MyndMed(TM) From TruShield(TM)
Via Investor Brand Network
InvestorNewsBreaks – BioAdaptives, Inc. (OTC Pink: BDPT) Prepares for National Launch of NeuroRush(TM) Nootropic in Late Summer 2025
Via Investor Brand Network
InvestorNewsBreaks – BioAdaptives, Inc. (OTC Pink: BDPT) to Launch Pawpa(TM) Regen Nationwide as Stem Cell-Based Canine Supplement Gains Momentum
Via Investor Brand Network
News headline image
BioAdaptives Announces National Launch of Pawpa™ Regen
From BioAdaptives Inc.
Via GlobeNewswire
InvestorNewsBreaks – Bioadaptives Inc (BDPT) Showcases Breakthrough Stem Cell Benefits in Regen Dog Chews
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Bioadaptives Inc (BDPT) Completes Successful Dosage Trials for Zeranovia™ Weight Loss Product
Via Investor Brand Network
BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris
Via Investor Brand Network

Frequently Asked Questions

Is Bioadaptives Inc publicly traded?
Yes, Bioadaptives Inc is publicly traded.
What exchange does Bioadaptives Inc trade on?
Bioadaptives Inc trades on the OTC Traded
What is the ticker symbol for Bioadaptives Inc?
The ticker symbol for Bioadaptives Inc is BDPT on the OTC Traded
What is the current price of Bioadaptives Inc?
The current price of Bioadaptives Inc is 0.0048
When was Bioadaptives Inc last traded?
The last trade of Bioadaptives Inc was at 09/25/26 03:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.